BioArctic AB
STO:BIOA B

Watchlist Manager
BioArctic AB Logo
BioArctic AB
STO:BIOA B
Watchlist
Price: 202 SEK -5.08% Market Closed
Market Cap: 17.8B SEK
Have any thoughts about
BioArctic AB?
Write Note

Net Margin
BioArctic AB

-139.3%
Current
-187%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-139.3%
=
Net Income
-232.9m
/
Revenue
167.1m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
SE
BioArctic AB
STO:BIOA B
17.9B SEK
-139%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
314.9B USD
9%
US
Amgen Inc
NASDAQ:AMGN
140.6B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
115.7B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.9B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.8B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-14%
Country SE
Market Cap 17.9B SEK
Net Margin
-139%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 314.9B USD
Net Margin
9%
Country US
Market Cap 140.6B USD
Net Margin
13%
Country US
Market Cap 115.7B USD
Net Margin
0%
Country US
Market Cap 103.9B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.7B AUD
Net Margin
18%
Country US
Market Cap 77.8B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36B EUR
Net Margin
-14%
No Stocks Found

BioArctic AB
Glance View

Market Cap
17.9B SEK
Industry
Biotechnology

In the heart of Sweden, BioArctic AB carves its niche as a pioneering biopharmaceutical company with a resolute focus on neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases. Founded in 2003 by the innovative minds of Professor Lars Lannfelt and Dr. Pär Gellerfors, the company draws on cutting-edge science to develop novel treatments that target the underlying causes of these debilitating conditions. BioArctic’s scientific journey is rooted in its strategic use of monoclonal antibodies to halt or reverse the progression of neurological diseases. By zeroing in on the amyloid beta proteins and alpha-synuclein aggregates that play significant roles in Alzheimer’s and Parkinson’s diseases, respectively, BioArctic aims to provide therapies that go beyond mere symptom management to address the fundamental disease processes. At the core of BioArctic’s financial engine lies its collaborative business model, where strategic partnerships with pharmaceutical giants like Eisai and AbbVie are pivotal. These alliances not only bolster BioArctic’s research capabilities but also generate substantial revenue through milestone payments and royalties. Such collaborations allow BioArctic to leverage the vast distribution networks and financial muscle of its partners, facilitating the global commercialization of its therapies once they achieve regulatory approval. As the company continues to advance its pipeline through rigorous clinical trials, its combination of scientific rigor and strategic partnerships positions it as a formidable player in the quest to unravel and treat complex neurodegenerative diseases. Through its relentless innovation and well-crafted alliances, BioArctic stands at the forefront of transforming medical treatment for millions worldwide.

BIOA B Intrinsic Value
219.28 SEK
Undervaluation 8%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-139.3%
=
Net Income
-232.9m
/
Revenue
167.1m
What is the Net Margin of BioArctic AB?

Based on BioArctic AB's most recent financial statements, the company has Net Margin of -139.3%.